Skip to content

For Patients

Q32 Bio is focused on developing innovative therapies for patients with alopecia areata and other autoimmune and inflammatory diseases in need of new treatment options.

photo_patients@2x

Q32 Bio Current Clinical Trials

logo_signal-aa

The SIGNAL-AA Phase 2a clinical trial is evaluating bempikibart (ADX-914) in patients with alopecia areata.

TRIAL STATUS: Part B recruiting

TRIAL INFORMATION: Part B of the SIGNAL-AA Phase 2a clinical trial is a multicenter, open-label study evaluating bempikibart in participants with severe or very severe alopecia areata (AA). The purpose of this study is to evaluate the efficacy and safety of bempikibart.

Learn more about bempikibart.

For more information about the SIGNAL-AA Phase 2a clinical trial or bempikibart, visit clinicaltrials.gov identifier: NCT06018428, or email: clinicaltrials@q32bio.com.

Expanded Access Policy

Q32 Bio focuses on conducting clinical trials to study the safety and efficacy of bempikibart in patients. These clinical trials are necessary for obtaining regulatory approval. We believe that participation in clinical trials is the most appropriate way for patients to access bempikibart before it is approved by a regulatory authority, and we believe regulatory approval is the best way to make safe and effective medications available to patients who may benefit. We do not offer any Expanded Access programs for bempikibart at this time. To learn more about our ongoing clinical trial for severe alopecia areata and to see if you may qualify, please visit our study posting on clinicaltrials.gov or email: clinicaltrials@q32bio.com.